Key US infectious-diseases centre to drop pandemic preparation

A significant shift is underway at the US National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes and centres at the National Institutes of Health (NIH). Staff have been instructed to remove the terms “biodefense” and “pandemic preparedness” from the institute’s online presence, signaling a major change in research priorities.

A New Focus for the NIAID

NIH director Jay Bhattacharya announced the restructuring on January 30th, describing it as a “complete transformation” away from the institute’s historical emphasis on HIV, biodefence, and pandemic preparedness. The NIAID will now concentrate more on basic immunology and infectious diseases currently impacting the United States population.

Did You Know? Approximately one-third of the NIAID’s $6.6 billion budget is currently allocated to projects focused on emerging infectious diseases and biodefence.

This change in direction comes after a period of scrutiny for both NIAID and its former director, Anthony Fauci, regarding public health measures implemented during the COVID-19 pandemic. Critics, including former President Donald Trump and other Republican politicians, have argued that these measures eroded public trust in health agencies.

Leadership Changes and a New Vision

The NIAID is currently led by acting director Jeffery Taubenberger, following the dismissal of infectious-disease physician Jeanne Marrazzo by the Trump administration. Bhattacharya, Taubenberger, and Taubenberger’s senior advisor, John Powers, outlined their “new vision” for the institute in a commentary published in Nature Medicine on January 16th.

According to the commentary, the NIAID’s previous work did not prevent the pandemic or mitigate the high levels of excess mortality experienced in the United States. The authors argue for a greater focus on allergic and autoimmune disorders, and common infections, citing their increasing prevalence.

Expert Insight: The decision to shift away from biodefence and pandemic preparedness research represents a significant recalibration of priorities, potentially impacting the nation’s ability to respond to future outbreaks or deliberate biological threats.

NIH principal deputy director Matthew Memoli has ordered a review of grant funding related to biodefence and pandemic preparedness in the coming weeks and months, according to four NIAID employees who spoke to Nature on the condition of anonymity.

Potential Implications

Nahid Bhadelia, director of Boston University’s Center on Emerging Infectious Diseases, expressed concern that deprioritizing these areas could leave the United States more vulnerable to evolving pathogens. She stated, “Just because we say we’re going to stop caring about these issues doesn’t make the issues go away — it just makes us less prepared.”

The NIH spokesperson stated that the new vision “sharpens its focus on the interconnected pillars of infectious diseases and immunology, expanding opportunities for research that address the most pressing challenges to Americans’ health today.” However, the agency declined to provide specifics regarding the restructuring plans.

Frequently Asked Questions

What is the NIAID doing differently?

The NIAID is shifting its focus from biodefence and pandemic preparedness to basic immunology and infectious diseases currently affecting people in the United States.

Who is currently leading the NIAID?

Jeffery Taubenberger is the acting director of the NIAID, following the dismissal of Jeanne Marrazzo.

What percentage of the NIAID’s budget is currently dedicated to emerging infectious diseases and biodefence?

Approximately one-third of the NIAID’s $6.6 billion budget is currently allocated to these areas.

As the NIAID undergoes this significant transformation, will this shift in focus adequately prepare the United States for the inevitable challenges posed by emerging infectious diseases and potential future pandemics?